Literature DB >> 8853251

Proposal for use of a standard side effect scoring system in studies exploring Helicobacter pylori treatment regimens.

W A de Boer1, J C Thys, T J Borody, D Y Graham, C O'Morain, G N Tytgat.   

Abstract

Many antibiotic regimens for treating Helicobacter pylori infection are currently used in clinical trials. The reported side-effect profiles of similar anti-Helicobacter therapies vary widely due to the use of different scoring systems. Therefore side-effect data from separate studies cannot be compared. Only randomized controlled trials will show how side-effect profiles and tolerability really differ between regimens, but few such studies are available. Therefore a choice of treatment based on side-effect profile is not possible at present. We seek standardization of side-effect registration among investigators and propose a side-effect questionnaire which, if generally accepted, would make it possible to compare data between trials.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8853251

Source DB:  PubMed          Journal:  Eur J Gastroenterol Hepatol        ISSN: 0954-691X            Impact factor:   2.566


  12 in total

1.  Improving compliance with helicobacter pylori eradication therapy: when and how?

Authors:  John P Anthony O'Connor; Ikue Taneike; Colm O'Morain
Journal:  Therap Adv Gastroenterol       Date:  2009-09       Impact factor: 4.409

2.  Dual proton pump inhibitor plus amoxicillin as an empiric anti-H. pylori therapy: studies from the United States.

Authors:  David Y Graham; Syed Ussama Javed; Sara Keihanian; Suhaib Abudayyeh; Antone R Opekun
Journal:  J Gastroenterol       Date:  2010-03-02       Impact factor: 7.527

3.  [Helicobacter eradication: an expensive Sisyphus task].

Authors:  H J Wildgrube
Journal:  Med Klin (Munich)       Date:  1998-07-15

4.  Nickel free-diet enhances the Helicobacter pylori eradication rate: a pilot study.

Authors:  M Campanale; E Nucera; V Ojetti; V Cesario; T A Di Rienzo; G D'Angelo; S Pecere; F Barbaro; G Gigante; T De Pasquale; A Rizzi; G Cammarota; D Schiavino; F Franceschi; A Gasbarrini
Journal:  Dig Dis Sci       Date:  2014-03-05       Impact factor: 3.199

5.  High-dose extended-release lansoprazole (dexlansoprazole) and amoxicillin dual therapy for Helicobacter pylori infections.

Authors:  Taraq A Attumi; David Y Graham
Journal:  Helicobacter       Date:  2014-04-03       Impact factor: 5.753

Review 6.  Furazolidone-based therapies for Helicobacter pylori infection: a pooled-data analysis.

Authors:  Angelo Zullo; Enzo Ierardi; Cesare Hassan; Vincenzo De Francesco
Journal:  Saudi J Gastroenterol       Date:  2012 Jan-Feb       Impact factor: 2.485

7.  Impact of Lactobacillus reuteri Supplementation on Anti-Helicobacter pylori Levofloxacin-Based Second-Line Therapy.

Authors:  Veronica Ojetti; Giovanni Bruno; Maria Elena Ainora; Giovanni Gigante; Gianluca Rizzo; Davide Roccarina; Antonio Gasbarrini
Journal:  Gastroenterol Res Pract       Date:  2012-05-29       Impact factor: 2.260

8.  Beyond Maastricht IV: are standard empiric triple therapies for Helicobacter pylori still useful in a South-European country?

Authors:  Nuno Almeida; Maria Manuel Donato; José Manuel Romãozinho; Cristina Luxo; Olga Cardoso; Maria Augusta Cipriano; Carol Marinho; Alexandra Fernandes; Carlos Calhau; Carlos Sofia
Journal:  BMC Gastroenterol       Date:  2015-02-15       Impact factor: 3.067

9.  Efficacy of rifabutin-based triple therapy as second-line treatment to eradicate helicobacter pylori infection.

Authors:  José M Navarro-Jarabo; Nuria Fernández; Francisca L Sousa; Encarnación Cabrera; Manuel Castro; Luz M Ramírez; Robin Rivera; Esther Ubiña; Francisco Vera; Isabel Méndez; Francisco Rivas-Ruiz; José L Moreno; Emilio Perea-Milla
Journal:  BMC Gastroenterol       Date:  2007-07-25       Impact factor: 3.067

10.  The Effect of Probiotic Plus Prebiotic Supplementation on the Tolerance and Efficacy of Helicobacter Pylori Eradication Quadruple Therapy: a Randomized Prospective Double Blind Controlled Trial.

Authors:  Afshin Shafaghi; Aydin Pourkazemi; Mohsen Khosravani; Saba Fakhrie Asl; Alireza Amir Maafi; Zahra Atrkar Roshan; Jafar Abaspour Rahimabad
Journal:  Middle East J Dig Dis       Date:  2016-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.